Phase 3 Readout
ONCO: Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C
August 31, 2028 · onc-392. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 31, 2028
- Company
- Onconetix, Inc. (ONCO)
- Drug
- onc-392
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C
- Company
- Onconetix, Inc. (ONCO)
- Drug
- onc-392
- Indication
- Non Small Cell Lung Cancer